Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-GLN PET/CT in Breast Cancer
NCT03863457Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-(2S,4R)4-fluoroglutamine in breast cancer, sponsored by Abramson Cancer Center. Primary endpoint: Kinetics and Biodistribution of [18F]F-GLN at 3 years. Started Apr 2019; status: recruiting.
02
Drugs
18F-(2S,4R)4-fluoroglutamine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03863457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863457.